دورية أكاديمية
أعرض في EDS

Natural Products for Liver Cancer Treatment: From Traditional Medicine to Modern Drug Discovery.

التفاصيل البيبلوغرافية
العنوان: Natural Products for Liver Cancer Treatment: From Traditional Medicine to Modern Drug Discovery.
المؤلفون: Kim DB; College of Korean Medicine, Kyung Hee University, Kyungheedae-ro 26 Dongdaemun-gu, Seoul 02447, Korea., Lee DK; College of Korean Medicine, Kyung Hee University, Kyungheedae-ro 26 Dongdaemun-gu, Seoul 02447, Korea., Cheon C; College of Korean Medicine, Kyung Hee University, Kyungheedae-ro 26 Dongdaemun-gu, Seoul 02447, Korea., Ribeiro RIMA; Laboratory of Experimental Pathology, Federal University of São João del Rei-CCO/UFSJ, Divinópolis 35501-296, Brazil., Kim B; College of Korean Medicine, Kyung Hee University, Kyungheedae-ro 26 Dongdaemun-gu, Seoul 02447, Korea.
المصدر: Nutrients [Nutrients] 2022 Oct 12; Vol. 14 (20). Date of Electronic Publication: 2022 Oct 12.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: MDPI Publishing Country of Publication: Switzerland NLM ID: 101521595 Publication Model: Electronic Cited Medium: Internet ISSN: 2072-6643 (Electronic) Linking ISSN: 20726643 NLM ISO Abbreviation: Nutrients Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI Publishing
مواضيع طبية MeSH: Liver Neoplasms*/pathology , Chemoembolization, Therapeutic*/adverse effects , Carcinoma, Hepatocellular*/pathology , Biological Products*/pharmacology , Biological Products*/therapeutic use , Antineoplastic Agents*/therapeutic use, Humans ; Sorafenib/therapeutic use ; Phenylurea Compounds/therapeutic use ; Niacinamide/adverse effects ; Drug Discovery ; Medicine, Traditional ; Treatment Outcome
مستخلص: Primary liver cancer was the seventh most diagnosed cancer and the second leading cause of cancer death with about 906,000 cases and 830,000 deaths, respectively, in 2020. Conventional treatment for liver cancer, such as transarterial chemoembolization (TACE) or sorafenib, has limitations in that there is the recurrence of cancer, drug inefficacy, and adverse effects. Traditional medicine and natural products of several regions including Korea, China, Europe, North America, India, and the Middle East have attracted a lot of attention since they have been reported to have anticancer effects with low adverse effects. In this review, several in vivo studies on the effects of natural compounds on liver cancer and clinical trials approving their therapeutic benefits were selected and discussed. As a result of the analysis of these studies, the effects of natural compounds were classified into a few mechanisms: apoptosis, anti-metastasis, and antiangiogenesis. In addition, medications including natural products in clinical trials were observed to exhibit improvements in various liver cancer symptoms and patients' survival rates. This study presents findings suggestive of the anticancer potential of natural products and their properties in relieving related symptoms.
References: Gastroenterology. 2016 Feb;150(2):488-98. (PMID: 26484708)
Int J Mol Sci. 2016 Jan 04;17(1):. (PMID: 26742032)
Free Radic Biol Med. 2017 Nov;112:597-607. (PMID: 28893626)
FEBS Lett. 2012 Jul 4;586(14):1959-70. (PMID: 22710176)
Front Pharmacol. 2021 Sep 02;12:738577. (PMID: 34539416)
J BUON. 2019 Sep-Oct;24(5):1950-1955. (PMID: 31786860)
World J Gastrointest Oncol. 2020 Oct 15;12(10):1091-1103. (PMID: 33133379)
BMC Complement Altern Med. 2017 Aug 22;17(1):418. (PMID: 28830415)
Int J Oncol. 2017 Aug;51(2):555-562. (PMID: 28714512)
Nutrients. 2021 Oct 27;13(11):. (PMID: 34836091)
EBioMedicine. 2017 Aug;22:58-67. (PMID: 28754304)
Integr Cancer Ther. 2016 Mar;15(1):87-95. (PMID: 26036624)
J Exp Ther Oncol. 2018 May;12(3):231-237. (PMID: 29790315)
Biomed Pharmacother. 2020 Jun;126:110064. (PMID: 32278271)
J Pain Symptom Manage. 2016 Jun;51(6):979-86. (PMID: 26921496)
Phytomedicine. 2021 Jul;87:153575. (PMID: 33984593)
Cancer Manag Res. 2019 Jun 28;11:5883-5894. (PMID: 31388314)
Eur J Cancer Prev. 2016 Jan;25(1):54-64. (PMID: 25747515)
Medchemcomm. 2018 May 16;9(6):1059-1068. (PMID: 30108995)
Biomed Pharmacother. 2017 May;89:332-341. (PMID: 28237915)
Food Chem Toxicol. 2019 Jul;129:229-238. (PMID: 31034933)
Biomed Res Int. 2019 Jun 25;2019:4696843. (PMID: 31341898)
Medicine (Baltimore). 2017 Jul;96(29):e7589. (PMID: 28723799)
Molecules. 2019 Jun 06;24(11):. (PMID: 31174320)
Mol Cancer Res. 2018 Feb;16(2):256-268. (PMID: 29187559)
Integr Cancer Ther. 2016 Sep;15(3):349-57. (PMID: 26590124)
Mol Cell Biochem. 2017 Sep;433(1-2):195-204. (PMID: 28397013)
Environ Toxicol. 2018 Jun 19;:. (PMID: 29923357)
Biofactors. 2018 Sep;44(5):496-502. (PMID: 30365229)
Phytother Res. 2011 Jan;25(1):1-10. (PMID: 20564543)
Chem Biol Interact. 2016 Aug 25;256:55-63. (PMID: 27369806)
Cold Spring Harb Perspect Med. 2015 Jul 17;5(9):a021535. (PMID: 26187874)
Eur J Med Chem. 2021 Nov 15;224:113690. (PMID: 34256124)
J Altern Complement Med. 2017 Aug;23(8):648-652. (PMID: 28375640)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
Am J Transl Res. 2017 Jun 15;9(6):2694-2711. (PMID: 28670362)
Exp Ther Med. 2018 Feb;15(2):1694-1701. (PMID: 29434755)
Cell Death Dis. 2018 Jun 7;9(6):689. (PMID: 29880886)
Biotechnol Adv. 2015 Dec;33(8):1582-1614. (PMID: 26281720)
Int Immunopharmacol. 2019 Oct;75:105765. (PMID: 31336335)
Front Oncol. 2019 Jun 26;9:545. (PMID: 31293977)
Oncotarget. 2016 Oct 25;7(43):70504-70515. (PMID: 27655700)
Biomed Pharmacother. 2021 May;137:111335. (PMID: 33581648)
Oncologist. 2021 Mar;26(3):e367-e373. (PMID: 33140457)
Nat Rev Cancer. 2008 Oct;8(10):782-98. (PMID: 18813321)
Cell Biochem Funct. 2020 Jun;38(4):490-499. (PMID: 31989689)
Cancer. 2018 May 15;124(10):2161-2168. (PMID: 29499082)
Med Sci Monit. 2021 Feb 01;27:e927727. (PMID: 33524008)
Toxics. 2018 Apr 17;6(2):. (PMID: 29673137)
Front Oncol. 2021 Apr 13;11:653902. (PMID: 33928038)
Z Naturforsch C J Biosci. 2016;71(7-8):201-8. (PMID: 27248120)
Pharmacol Res. 2019 Jun;144:210-226. (PMID: 31022523)
Molecules. 2016 Nov 10;21(11):. (PMID: 27834930)
Chin J Integr Med. 2020 May;26(5):370-374. (PMID: 30810974)
Asian J Pharm Sci. 2017 Sep;12(5):442-455. (PMID: 32104357)
J Ethnopharmacol. 2019 Apr 6;233:190-196. (PMID: 30639232)
Biochim Biophys Acta Rev Cancer. 2020 Jan;1873(1):188314. (PMID: 31682895)
Regul Toxicol Pharmacol. 2020 Jun;113:104642. (PMID: 32197968)
Pediatr Blood Cancer. 2020 Nov;67(11):e28655. (PMID: 32798298)
Chin J Nat Med. 2018 Jan;16(1):29-40. (PMID: 29425588)
Biomolecules. 2019 Oct 07;9(10):. (PMID: 31591318)
Cancer Prev Res (Phila). 2018 Dec;11(12):797-810. (PMID: 30446518)
Cancer Cell Int. 2020 Aug 05;20:371. (PMID: 32774165)
Anticancer Agents Med Chem. 2020;20(9):1147-1156. (PMID: 32106805)
Front Mol Neurosci. 2011 Dec 02;4:51. (PMID: 22144946)
Nat Rev Drug Discov. 2021 Mar;20(3):200-216. (PMID: 33510482)
معلومات مُعتمدة: NRF-2020R1I1A2066868 Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education; No. 2020R1A5A2019413 the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT); HF20C0116 a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea; HF20C0038 grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea
فهرسة مساهمة: Keywords: anti-metastasis; antiangiogenesis; anticancer; apoptosis; hepatic cancer; liver cancer; natural compounds; natural products
المشرفين على المادة: 9ZOQ3TZI87 (Sorafenib)
0 (Phenylurea Compounds)
25X51I8RD4 (Niacinamide)
0 (Biological Products)
0 (Antineoplastic Agents)
تواريخ الأحداث: Date Created: 20221027 Date Completed: 20221028 Latest Revision: 20221030
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC9610711
DOI: 10.3390/nu14204252
PMID: 36296934
قاعدة البيانات: MEDLINE
الوصف
تدمد:2072-6643
DOI:10.3390/nu14204252